Literature DB >> 6335664

Adverse effects from metoprolol are not generally associated with oxidation status.

D W Clark, A K Morgan, H Waal-Manning.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6335664      PMCID： PMC1463667          DOI： 10.1111/j.1365-2125.1984.tb02573.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

1.  Protecting poor metabolizers, a group at high risk of adverse drug reactions.

Authors:  J R Idle; N S Oates; R R Shah; R L Smith
Journal:  Lancet       Date:  1983-06-18       Impact factor: 79.321

2.  Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.

Authors:  M S Lennard; J H Silas; S Freestone; J Trevethick
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

3.  Oxidation phenotype--a major determinant of metoprolol metabolism and response.

Authors:  M S Lennard; J H Silas; S Freestone; L E Ramsay; G T Tucker; H F Woods
Journal:  N Engl J Med       Date:  1982-12-16       Impact factor: 91.245

4.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

5.  Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.

Authors:  M Eichelbaum; L Bertilsson; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

6.  Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.

Authors:  R R Shah; N S Oates; J R Idle; R L Smith; J D Lockhart
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-30
  6 in total
  7 in total

1.  Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects.

Authors:  R V Lewis; L E Ramsay; P R Jackson; W W Yeo; M S Lennard; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

2.  CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.

Authors:  Jasmine A Luzum; Kevin M Sweet; Philip F Binkley; Tara J Schmidlen; Joseph P Jarvis; Michael F Christman; Wolfgang Sadee; Joseph P Kitzmiller
Journal:  Pharm Res       Date:  2017-02-08       Impact factor: 4.200

3.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 4.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

5.  Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate.

Authors:  Angela Seeringer; Jürgen Brockmöller; Steffen Bauer; Julia Kirchheiner
Journal:  Eur J Clin Pharmacol       Date:  2008-06-11       Impact factor: 2.953

Review 6.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

7.  Adverse drug reaction reporting and retrospective phenotyping for oxidation polymorphism.

Authors:  D W Clark; I R Edwards
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.